(Q35557370)

8 August 2017

1 reference

title

Autoimmune aspects of cytokine and anticytokine therapies (English)

1 reference

8 August 2017

4

Yehuda Shoenfeld

1 reference

8 August 2017

2

Guido Valesini

1 reference

8 August 2017

3

Rossana Scrivo

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14553875

20 March 2024

author name string

Irit Krause

1

1 reference

8 August 2017

language of work or name

English

0 references

publication date

1 October 2003

1 reference

full work available at URL

8 August 2017

https://api.elsevier.com/content/article/PII:S0002934303003905?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0002-9343(03)00390-5

https://api.elsevier.com/content/article/PII:S0002934303003905?httpAccept=text/plain

20 March 2024

1 reference

https://api.crossref.org/works/10.1016/S0002-9343(03)00390-5

American Journal of Medicine

20 March 2024

published in

1 reference

8 August 2017

volume

115

1 reference

8 August 2017

issue

5

1 reference

8 August 2017

page(s)

390-397

1 reference

Tumor necrosis factor alpha blockers and the induction of anti-DNA autoantibodies

8 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900390-5

Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900390-5

Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900390-5

Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900390-5

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900390-5

Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900390-5

RETRACTED: Infliximab in patients with primary Sjögren's syndrome: a pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900390-5

Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900390-5

Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900390-5

Etanercept therapy in children with treatment-resistant uveitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900390-5

Remission of Behçet's syndrome with tumour necrosis factor alpha blocking therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900390-5

Adult onset Still's disease: response to Enbrel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900390-5

Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900390-5

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900390-5

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900390-5

Drug-induced systemic lupus erythematosus associated with etanercept therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900390-5

Drug-induced systemic lupus erythematosus and TNF-alpha blockers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900390-5

Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900390-5

Tumour necrosis factor-alpha in murine autoimmune 'lupus' nephritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900390-5

Chronic therapy with recombinant tumor necrosis factor-alpha in autoimmune NZB/NZW F1 mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900390-5

Accelerated autoimmunity and lupus nephritis in NZB mice with an engineered heterozygous deficiency in tumor necrosis factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900390-5

Impaired tumour necrosis factor-alpha (TNF-alpha) production and abnormal B cell response to TNF-alpha in patients with systemic lupus erythematosus (SLE).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900390-5

In vivo neutralization of TNF-alpha promotes humoral autoimmunity by preventing the induction of CTL

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900390-5

Anticardiolipin antibodies in rheumatoid patients treated with etanercept or conventional combination therapy: direct and indirect evidence for a possible association with infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900390-5

Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900390-5

Multiple sclerosis and chronic inflammatory diseases. A case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900390-5

Experimental autoimmune encephalomyelitis: immunotherapy with anti-tumor necrosis factor antibodies and soluble tumor necrosis factor receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900390-5

TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900390-5

Autoimmune skin rashes associated with etanercept for rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900390-5

Accelerated nodulosis and vasculitis following etanercept therapy for rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900390-5

Bullous skin lesions following infliximab infusion in a patient with rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900390-5

Nephrotic syndrome associated with anti-tumor necrosis factor alpha therapy in a patient with rheumatoid arthritis: comment on the article by Charles et al

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900390-5

The interferons. Mechanisms of action and clinical applications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900390-5

Modification of hepatitis B virus infection by recombinant leukocyte alpha A interferon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900390-5

Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900390-5

Alpha-2 interferon therapy of hairy-cell leukemia: a multicenter study of 64 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900390-5

Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900390-5

Autoimmune Phenomena in Patients with Malignant Carcinoid Tumors During Interferon-α Treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900390-5

PRIMARY HYPOTHYROIDISM ASSOCIATED WITH INTERFERON THERAPY OF BREAST CANCER

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900390-5

Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alpha-2a

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900390-5

A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900390-5

Side effects of high-dose interferon therapy for chronic hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900390-5

Immune-mediated and unusual complications during interferon alfa therapy in chronic myelogenous leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900390-5

Antibodies against double-stranded DNA and development of polymyositis during treatment with interferon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900390-5

Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900390-5

Development of systemic lupus erythematosus after interferon therapy for chronic myelogenous leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900390-5

Systemic lupus erythematosus following interferon therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900390-5

Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900390-5

Lupus-like autoimmune disease induced by interferon therapy for myeloproliferative disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900390-5

Incomplete Reiter's syndrome induced by systemic interferon alpha treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900390-5

Severe exacerbation of hepatitis C-associated vasculitic neuropathy following treatment with interferon alpha: a case report and literature review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900390-5

It is hazardous to treat HIV patients with interferon-alpha

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900390-5

Enhancement by interferon of the specific cytotoxicity of sensitized lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900390-5

A Molecular Basis for MHC Class II—Associated Autoimmunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900390-5

Interferon-alpha up-regulates bcl-2 expression and protects B-CLL cells from apoptosis in vitro and in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900390-5

High levels of bcl-2 protein in circulating T lymphocytes, but not B lymphocytes, of patients with systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900390-5

Interferon-alpha-induced human lupus inclusions and p36 protein in cancer and AIDS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900390-5

Interferon alpha increases the frequency of interferon gamma-producing human CD4+ T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900390-5

T helper cell subsets in insulin-dependent diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900390-5

Interferon and serum thyroid hormones

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900390-5

Interferon-alpha and interferon-gamma reduce excessive collagen synthesis and procollagen mRNA levels of scleroderma fibroblasts in culture

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900390-5

Autoantibodies in multiple sclerosis patients before and during IFN-beta 1b treatment: are they correlated with the occurrence of autoimmune diseases?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900390-5

Interferon beta decreases T cell activation and interferon gamma production in multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900390-5

Immunomodulatory properties of interferon-gamma. An update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900390-5

Interferon-gamma and host antimicrobial defense: current and future clinical applications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900390-5

A randomized, double-blind study comparing twenty-four-week treatment with recombinant interferon-gamma versus placebo in the treatment of rheumatoid arthritis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900390-5

Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900390-5

A Controlled Trial of Interferon Gamma to Prevent Infection in Chronic Granulomatous Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900390-5

Induction of antinuclear antibodies in patients with rheumatoid arthritis receiving treatment with human recombinant interferon gamma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900390-5

In vivo treatment of (NZB X NZW)F1 lupus-like nephritis with monoclonal antibody to gamma interferon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900390-5

Antinuclear autoantibodies and lupus nephritis in transgenic mice expressing interferon gamma in the epidermis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900390-5

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900390-5

Hypothyroidism during immunotherapy with interleukin-2 is associated with antithyroid antibodies and response to treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900390-5

Autoimmunity resulting from cytokine treatment predicts long-term survival in patients with metastatic renal cell cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900390-5

Chronic inflammatory arthritis after treatment with high-dose interleukin-2 for malignancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900390-5

Rheumatic disease following immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900390-5

Myositis associated with interleukin-2 therapy in a patient with metastatic renal cell carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900390-5

Soluble interleukin-2 receptor, interleukin-2 and interleukin-4 in sera and supernatants from patients with progressive systemic sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900390-5

Interleukin-2 in scleroderma: correlation of serum level with extent of skin involvement and disease duration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900390-5

Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis

7 January 2021

13

1 reference

https://api.crossref.org/works/10.1016/S0002-9343(03)00390-5

Leukocytoclastic vasculitis due to etanercept

20 March 2024

33

1 reference

https://api.crossref.org/works/10.1016/S0002-9343(03)00390-5

Alfa-2b interferon in the treatment of Hodgkin's disease and non-Hodgkin's lymphoma

20 March 2024

43

1 reference

https://api.crossref.org/works/10.1016/S0002-9343(03)00390-5

Induction of systemic lupus erythematosus by interferon-gamma in a patient with rheumatoid arthritis

20 March 2024

78

1 reference

https://api.crossref.org/works/10.1016/S0002-9343(03)00390-5

Interferon-gamma induced exacerbation of systemic lupus erythematosus

20 March 2024

79

1 reference

https://api.crossref.org/works/10.1016/S0002-9343(03)00390-5

Serum levels of interferons in patients with systemic lupus erythematosus

20 March 2024

82

1 reference

https://api.crossref.org/works/10.1016/S0002-9343(03)00390-5

Rapid exacerbation of scleroderma in a patient treated with interleukin 2 and lymphokine activated killer cells for renal cell carcinoma

20 March 2024

91

1 reference

https://api.crossref.org/works/10.1016/S0002-9343(03)00390-5

20 March 2024

Identifiers

1 reference

8 August 2017

1 reference